<- Go Home
Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Market Cap
$92.8M
Volume
160.2K
Cash and Equivalents
$77.0M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$12.90
52 Week Low
$2.14
Dividend
N/A
Price / Book Value
2.22
Price / Earnings
-1.43
Price / Tangible Book Value
2.22
Enterprise Value
$15.8M
Enterprise Value / EBITDA
N/A
Operating Income
-$42.5M
Return on Equity
7317.41%
Return on Assets
-63.50
Cash and Short Term Investments
$77.0M
Debt
N/A
Equity
$41.9M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium